{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1380864116842740480.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Tomohide Tamura"}],"foaf:familyName":[{"@value":"Tamura"}],"foaf:givenName":[{"@value":"Tomohide"}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1360864116842740352","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.1016/j.jtocrr.2021.100171"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S2666364321000308?httpAccept=text/xml"},{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S2666364321000308?httpAccept=text/plain"}],"notation":[{"@value":"Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.jtocrr.2021.100171_aSoSDoJFJHaaDEfA4dmxtw4qNKg"},{"@type":"OPENAIRE","@value":"doi_dedup___::67cacb8d9ea8335fcfeea0c230bd1fb5_XgoJMg3pv20G9LnVdID5HVDAqWI"}]}